South Africa: THE ALPS IN MZANSI: Second Medical Use Claims In South African Patent Law

Last Updated: 6 April 2017
Article by Ursula Baravalle

South Africa has the largest pharmaceutical products market in Africa, with the pharmaceutical industry playing a very important role in the South African economy. Patentability is the economic driver for research and innovation. Furthermore, contrary to the fear that patentability may curtail access to medicines by making them more expensive, it is patentability itself that serves as the economic incentive with respect to the manufacture and distribution of various drugs within an economy.

Applicants are often unfamiliar with the position of second medical uses (new uses of known pharmaceutical compounds), of method of treatment claims and Swiss-type claims in South Africa due to the significant differences in legislation compared to other jurisdictions such as Europe and the USA.

Method of Treatment Claims

Method of treatment claims "A method of treating [condition Y] comprising administering [compound X]" are not allowable in South Africa.

Second Medical Use Claims

In Europe, under the EPC 2000 claim form, second medical uses "[Compound X]* for use in the treatment of [condition Y]" are allowable. *where compound X is a known compound

Strictly speaking, South Africa does not permit patents covering any new uses of known pharmaceutical compounds (second medical use claims). Following the original European provision, the Patents Act provides that a known substance can only be claimed for use in a method of medical treatment the first time that it is disclosed as being useful in a medical treatment. This has been confirmed by the South African courts.

Once the use of the compound in a method of medical treatment has formed part of the state of the art, it cannot then be claimed a second time in respect of a new medical use.

In order to overcome this prohibition, South Africa has adopted the Swiss form of claiming to provide protection in instances where a second medical use is sought to be protected, and hence serves as a mechanism by which second medical uses are protectable in South Africa albeit through the Swiss from and not via direct protection of the second medical use.

Swiss-Type Claims

Swiss-type claims follow the form "Use of [compound X] in the manufacture of a medicament for the treatment of [condition Y]".

The Swiss claim focuses on the method of manufacture. Hence, once disclosed this method will then form part of the prior art and, for this reason, any subsequent Swiss-type claims that vary the dosage regimes may not be patentable.

However, this aspect of Swiss claiming has not been tested in the South African courts and therefore we do not have an unequivocal answer with respect to the South African position. It may well be that a Swiss claim characterised by a certain dosage regime may be considered to be patentable.

The effect of the different claim formulations on patentability in South Africa may be summarised as follows:

  • Method of treatment claims are not patentable in South Africa.
  • Second medical use claims are not patentable in South Africa.
  • Swiss-type claims are patentable in South Africa.

In terms of a policy that is currently in draft form, South Africa is considering implementing a substantive patent examination system (the current examination system being a depository system) and pre- and post grant opposition procedures as a means to prevent patent ever-greening.

The policy also suggests that the government systems with respect to patents and with respect to the registration of medicines should be aligned. The purpose of this alignment would be to prevent the granting of patents to medicines that may be expiring and to thereby prevent access to public health being undermined. The policy also specifically states that South African legislation must allow strict rules to apply and should exclude new uses of known products.

In an effort to promote such access, including access to medicines at lower prices, South Africa is currently considering utilizing the mechanism of compulsory licensing to urge patent holders to license the manufacturing rights to third parties and to thereby allow for a reduction in price.

Although the issue of compulsory licensing does not speak directly to the issue of the allowability of second medical use claims, it does speak directly towards the South African position as regards access to medicines and the tendency to want to move towards a patent system which, it would appear, is not intended to favour second medical use claims.

As regards generic medications, the so-called Bolar provision applies in South Africa. This provision allows the generic companies to have completed the requisite regulatory approval processes prior to the expiration of the patent so that upon expiration of the patent they are entitled to enter into the market. The law does not, however, allow for stockpiling.


Swiss claims are allowable in South Africa and hence the pharmaceutical industry may still obtain protection in respect of second medical uses using this type of claim format.

We recommend against the inclusion of both method of treatment claims and EPC 2000 claim forms as these are not permissible in South Africa.

Originally published 4 May 2016

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.